LINC01447: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: LINC01447

NCBI ID: G101929086

LINC01447

Other Name(s): long intergenic non-protein coding RNA 1447 | Long intergenic non-protein coding RNA 1447

LINC01447: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

LINC01447 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique structure, length, and composition, which makes it an interesting candidate as a drug target or biomarker. The purpose of this article is to provide an overview of LINC01447, its potential drug targets, and its potential as a biomarker.

Structure and Function

LINC01447 is a transcribed RNA molecule that contains 21 exons and an alternate reading frame. It has a unique feature, known as its polycombination, which allows it to form a stable RNA structure that can be translated into a protein. LINC01447 has a calculated molecular weight of 13.9 kDa and a base pairing pattern of G/C 72%, A/T 28%, and C/G 60%.

LINC01447 is expressed in various tissues and cells in the body, including the brain, heart, liver, and muscle. It has been shown to be involved in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

Potential Drug Targets

LINC01447 is a good candidate as a drug target due to its unique structure and function. Its polycombination and stable RNA structure make it a potential protein target that can be modulated with small molecules. Several studies have shown that LINC01447 can be targeted with small molecules, including inhibitors of tyrosine kinase activity and inhibitors of mTOR signaling. These small molecules have been shown to interact with LINC01447 and alter its stability and function.

In addition to its potential as a drug target, LINC01447 has also been shown to be a potential biomarker. Its expression has been shown to be associated with various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Additionally, its expression has been shown to be regulated by various factors, including DNA methylation and histone modification.

Potential Biomarkers

LINC01447 has also been shown to be a potential biomarker for various diseases. Its expression has been associated with various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, LINC01447 has been shown to be overexpressed in various cancer types and has been used as a biomarker for cancer diagnosis and treatment.

Additionally, LINC01447 has been shown to be involved in various signaling pathways that are involved in the development and progression of neurodegenerative diseases. Its expression has been shown to be regulated by various factors, including DNA methylation and histone modification, which are involved in the regulation of neurodegenerative diseases.

Conclusion

LINC01447 is a long non-coding RNA that has unique structure and function. Its polycombination and stable RNA structure make it a potential protein target that can be modulated with small molecules. Its expression has been associated with various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases, and has also been shown to be a potential biomarker. Further research is needed to fully understand the role of LINC01447 in disease and to develop it as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1447

The "LINC01447 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01447 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets